Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 5/2009

01-05-2009 | Article

n-3 Fatty acids and rosiglitazone improve insulin sensitivity through additive stimulatory effects on muscle glycogen synthesis in mice fed a high-fat diet

Authors: O. Kuda, T. Jelenik, Z. Jilkova, P. Flachs, M. Rossmeisl, M. Hensler, L. Kazdova, N. Ogston, M. Baranowski, J. Gorski, P. Janovska, V. Kus, J. Polak, V. Mohamed-Ali, R. Burcelin, S. Cinti, M. Bryhn, J. Kopecky

Published in: Diabetologia | Issue 5/2009

Login to get access

Abstract

Aims/hypothesis

Fatty acids of marine origin, i.e. docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) act as hypolipidaemics, but they do not improve glycaemic control in obese and diabetic patients. Thiazolidinediones like rosiglitazone are specific activators of peroxisome proliferator-activated receptor γ, which improve whole-body insulin sensitivity. We hypothesised that a combined treatment with a DHA and EPA concentrate (DHA/EPA) and rosiglitazone would correct, by complementary additive mechanisms, impairments of lipid and glucose homeostasis in obesity.

Methods

Male C57BL/6 mice were fed a corn oil-based high-fat diet. The effects of DHA/EPA (replacing 15% dietary lipids), rosiglitazone (10 mg/kg diet) or a combination of both on body weight, adiposity, metabolic markers and adiponectin in plasma, as well as on liver and muscle gene expression and metabolism were analysed. Euglycaemic–hyperinsulinaemic clamps were used to characterise the changes in insulin sensitivity. The effects of the treatments were also analysed in dietary obese mice with impaired glucose tolerance (IGT).

Results

DHA/EPA and rosiglitazone exerted additive effects in prevention of obesity, adipocyte hypertrophy, low-grade adipose tissue inflammation, dyslipidaemia and insulin resistance, while inducing adiponectin, suppressing hepatic lipogenesis and decreasing muscle ceramide concentration. The improvement in glucose tolerance reflected a synergistic stimulatory effect of the combined treatment on muscle glycogen synthesis and its sensitivity to insulin. The combination treatment also reversed dietary obesity, dyslipidaemia and IGT.

Conclusions/interpretation

DHA/EPA and rosiglitazone can be used as complementary therapies to counteract dyslipidaemia and insulin resistance. The combination treatment may reduce dose requirements and hence the incidence of adverse side effects of thiazolidinedione therapy.
Appendix
Available only for authorised users
Literature
1.
Ruxton CH, Reed SC, Simpson Double Dagger MJ, Millington KJ (2004) The health benefits of omega-3 polyunsaturated fatty acids: a review of the evidence. J Hum Nutr Diet 17:449−459CrossRefPubMed
2.
MacLean CH, Konica WA, Morton SC et al (2004) Effects of omega-3 fatty acids on lipids and glycemic control in type II diabetes and the metabolic syndrome and on inflammatory bowel disease, rheumatoid arthritis, renal disease, systemic lupus erythematosus, and osteoporosis. Evid Rep Technol Assess (Summ) 89:1−4
3.
Nettleton JA, Katz R (2005) n - 3 long-chain polyunsaturated fatty acids in type 2 diabetes: a review. J Am Diet Assoc 105:428−440CrossRefPubMed
4.
Mori TA, Bao DQ, Burke V, Puddey IB, Watts GF, Beilin LJ (1999) Dietary fish as a major component of a weight-loss diet: effect on serum lipids, glucose, and insulin metabolism in overweight hypertensive subjects. Am J Clin Nutr 70:817−825PubMed
5.
Couet C, Delarue J, Ritz P, Antoine J-M, Lamisse F (1997) Effect of dietary fish oil on body fat mass and basal fat oxidation in healthy adults. Int J Obes 21:637−643CrossRef
6.
Fasching P, Ratheiser K, Waldhausl W et al (1991) Metabolic effects of fish-oil supplementation in patients with impaired glucose tolerance. Diabetes 40:583−589CrossRefPubMed
7.
Pelikanova T, Kohout M, Valek J, Kazdova L, Base J (1993) Metabolic effects of omega-3 fatty acids in type 2 (non-insulin-dependent) diabetic patients. Ann NY Acad Sci 683:272−278CrossRefPubMed
8.
Ikemoto S, Takahashi M, Tsunoda N, Maruyama K, Itakura H, Ezaki O (1996) High-fat diet-induced hyperglycemia and obesity in mice: differential effects of dietary oils. Metabolism 45:1539−1546CrossRefPubMed
9.
Ruzickova J, Rossmeisl M, Prazak T et al (2004) Omega-3 PUFA of marine origin limit diet-induced obesity in mice by reducing cellularity of adipose tissue. Lipids 39:1177−1185CrossRefPubMed
10.
Flachs P, Horakova O, Brauner P et al (2005) Polyunsaturated fatty acids of marine origin upregulate mitochondrial biogenesis and induce beta-oxidation in white fat. Diabetologia 48:2365−2375CrossRefPubMed
11.
Storlien LH, Kraegen EW, Chisholm DJ, Ford GL, Bruce DG, Pascoe WS (1987) Fish oil prevents insulin resistance induced by high-fat feeding in rats. Science 237:885−888CrossRefPubMed
12.
Neschen S, Morino K, Dong J et al (2007) n - 3 fatty acids preserve insulin sensitivity in vivo in a PPAR-alpha-dependent manner. Diabetes 56:1034−1041CrossRefPubMed
13.
Sanderson LM, de Groot PJ, Hooiveld GJ et al (2008) Effect of synthetic dietary triglycerides: a novel research paradigm for nutrigenomics. PLoS ONE 3:e1681CrossRefPubMed
14.
Jump DB (2004) Fatty acid regulation of gene transcription. Crit Rev Clin Lab Sci 41:41−78PubMed
15.
Neschen S, Morino K, Rossbacher JC et al (2006) Fish oil regulates adiponectin secretion by a peroxisome proliferator-activated receptor-dependent mechanism in mice. Diabetes 55:924−928CrossRefPubMed
16.
Serhan CN (2005) Novel omega-3-derived local mediators in anti-inflammation and resolution. Pharmacol Ther 105:7−21PubMed
17.
Teran-Garcia M, Adamson AW, Yu G et al (2007) Polyunsaturated fatty acid suppression of fatty acid synthase (FASN): evidence for dietary modulation of NF-Y binding to the Fasn promoter by SREBP-1c. Biochem J 402:591−600PubMed
18.
Jucker BM, Cline GW, Barucci N, Shulman GI (1999) Differential effects of safflower oil versus fish oil feeding on insulin-stimulated glycogen synthesis, glycolysis, and pyruvate dehydrogenase flux in skeletal muscle: a 13C nuclear magnetic resonance study. Diabetes 48:134−140CrossRefPubMed
19.
Goldberg RB, Kendall DM, Deeg MA et al (2005) A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 28:1547−1554PubMed
20.
Yang X, Smith U (2007) Adipose tissue distribution and risk of metabolic disease: does thiazolidinedione-induced adipose tissue redistribution provide a clue to the answer? Diabetologia 50:1127−1139PubMed
21.
Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356:2457−2471PubMed
22.
Lazarenko OP, Rzonca SO, Hogue WR, Swain FL, Suva LJ, Lecka-Czernik B (2007) Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology 148:2669−2680CrossRefPubMed
23.
Kim JK, Fillmore JJ, Gavrilova O et al (2003) Differential effects of rosiglitazone on skeletal muscle and liver insulin resistance in A-ZIP/F-1 fatless mice. Diabetes 52:1311−1318PubMed
24.
Tsuchida A, Yamauchi T, Takekawa S et al (2005) Peroxisome proliferator-activated receptor (PPAR)alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARalpha, PPARgamma, and their combination. Diabetes 54:3358−3370CrossRefPubMed
25.
Kim H, Haluzik M, Gavrilova O et al (2004) Thiazolidinediones improve insulin sensitivity in adipose tissue and reduce the hyperlipidaemia without affecting the hyperglycaemia in a transgenic model of type 2 diabetes. Diabetologia 47:2215−2225CrossRefPubMed
26.
Lebrasseur NK, Kelly M, Tsao TS et al (2006) Thiazolidinediones can rapidly activate AMP-activated protein kinase (AMPK) in mammalian tissues. Am J Physiol Endocrinol Metab 291(1):E175−E181CrossRefPubMed
27.
Wilson-Fritch L, Nicoloro S, Chouinard M et al (2004) Mitochondrial remodeling in adipose tissue associated with obesity and treatment with rosiglitazone. J Clin Invest 114:1281−1289PubMed
28.
Hevener AL, Olefsky JM, Reichart D et al (2007) Macrophage PPAR gamma is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones. J Clin Invest 117:1658−1669CrossRefPubMed
29.
Riserus U, Tan GD, Fielding BA et al (2005) Rosiglitazone increases indexes of stearoyl-CoA desaturase activity in humans: link to insulin sensitization and the role of dominant-negative mutation in peroxisome proliferator-activated receptor-gamma. Diabetes 54:1379−1384CrossRefPubMed
30.
Todoric J, Loffler M, Huber J et al (2006) Adipose tissue inflammation induced by high-fat diet in obese diabetic mice is prevented by n - 3 polyunsaturated fatty acids. Diabetologia 49:2109−2119CrossRefPubMed
31.
Flachs P, Mohamed-Ali V, Horakova O et al (2006) Polyunsaturated fatty acids of marine origin induce adiponectin in mice fed high-fat diet. Diabetologia 49:394−397CrossRefPubMed
32.
33.
Polak J, Kovacova Z, Jacek M et al (2007) An increase in plasma adiponectin multimeric complexes follows hypocaloric diet-induced weight loss in obese and overweight pre-menopausal women. Clin Sci (Lond) 112:557−565
34.
Baranowski M, Zabielski P, Blachnio A, Gorski J (2008) Effect of exercise duration on ceramide metabolism in the rat heart. Acta Physiol (Oxf) 192:519−529
35.
Pravenec M, Kazdova L, Landa V et al (2003) Transgenic and recombinant resistin impair skeletal muscle glucose metabolism in the spontaneously hypertensive rat. J Biol Chem 278:45209−45215CrossRefPubMed
36.
Rossmeisl M, Kovar J, Syrovy I et al (2005) Triglyceride-lowering effect of respiratory uncoupling in white adipose tissue. Obes Res 13:835−844CrossRefPubMed
37.
Haemmerle G, Zimmermann R, Hayn M et al (2002) Hormone-sensitive lipase deficiency in mice causes diglyceride accumulation in adipose tissue, muscle, and testis. J Biol Chem 277:4806−4815PubMed
38.
Cinti S, Mitchell G, Barbatelli G et al (2005) Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res 46:2347−2355CrossRefPubMed
39.
Burcelin R, Crivelli V, Dacosta A, Roy-Tirelli A, Thorens B (2002) Heterogeneous metabolic adaptation of C57BL/6J mice to high-fat diet. Am J Physiol Endocrinol Metab 282:E834−E842PubMed
40.
Park SY, Kim HJ, Wang S et al (2005) Hormone-sensitive lipase knockout mice have increased hepatic insulin sensitivity and are protected from short-term diet-induced insulin resistance in skeletal muscle and heart. Am J Physiol Endocrinol Metab 289:E30−E39CrossRefPubMed
41.
Rossetti L, Giaccari A (1990) Relative contribution of glycogen synthesis and glycolysis to insulin-mediated glucose uptake. A dose−response euglycemic clamp study in normal and diabetic rats. J Clin Invest 85:1785−1792CrossRefPubMed
42.
Bonen A, Clark MG, Henriksen EJ (1994) Experimental approaches in muscle metabolism: hindlimb perfusion and isolated muscle incubations. Am J Physiol 266:E1−E16PubMed
43.
Okuno A, Tamemoto H, Tobe K et al (1998) Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 101:1354−1361CrossRefPubMed
44.
Gahceci M, Gokalp D, Bahceci S, Tuzcu A, Atmaca S, Arikan S (2007) The correlation between adiposity and adiponectin, tumor necrosis factor alpha, interleukin-6 and high sensitivity C-reactive protein levels. Is adipocyte size associated with inflammation in adults? J Endocrinol Invest 30:210−214
45.
Pajvani UB, Hawkins M, Combs TP et al (2004) Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 279:12152−12162PubMed
46.
Baker PW, Gibbons GF (2000) Effect of dietary fish oil on the sensitivity of hepatic lipid metabolism to regulation by insulin. J Lipid Res 41:719−726PubMed
47.
Laplante M, Festuccia WT, Soucy G et al (2009) Tissue-specific postprandial clearance is the major determinant of PPAR-gamma-induced triglyceride lowering in the rat. Am J Physiol Regul Integr Comp Physiol 296:R57−R66PubMed
48.
Ton MN, Chang C, Carpentier YA, Deckelbaum RJ (2005) In vivo and in vitro properties of an intravenous lipid emulsion containing only medium chain and fish oil triglycerides. Clin Nutr 24:492−501CrossRefPubMed
49.
Suchankova G, Tekle M, Saha AK, Ruderman NB, Clarke SD, Gettys TW (2005) Dietary polyunsaturated fatty acids enhance hepatic AMP-activated protein kinase activity in rats. Biochem Biophys Res Commun 326:851−858CrossRefPubMed
50.
Gibbons GF, Wiggins D, Brown AM, Hebbachi AM (2004) Synthesis and function of hepatic very-low-density lipoprotein. Biochem Soc Trans 32:59−64CrossRefPubMed
Metadata
Title
n-3 Fatty acids and rosiglitazone improve insulin sensitivity through additive stimulatory effects on muscle glycogen synthesis in mice fed a high-fat diet
Authors
O. Kuda
T. Jelenik
Z. Jilkova
P. Flachs
M. Rossmeisl
M. Hensler
L. Kazdova
N. Ogston
M. Baranowski
J. Gorski
P. Janovska
V. Kus
J. Polak
V. Mohamed-Ali
R. Burcelin
S. Cinti
M. Bryhn
J. Kopecky
Publication date
01-05-2009
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 5/2009
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-009-1305-z

Other articles of this Issue 5/2009

Diabetologia 5/2009 Go to the issue

For Debate

Glucose allostasis: Emperor’s new clothes?

Article

Sex-related psychological effects on metabolic control in type 2 diabetes mellitus

Commentary

A role for islet neogenesis in curing diabetes

Article

Involvement of TNF-α in abnormal adipocyte and muscle sortilin expression in obese mice and humans

Letter

GlaxoSmithKline responds to the consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

Article

Investigation of DNA polymorphisms in SMAD genes for genetic predisposition to diabetic nephropathy in patients with type 1 diabetes mellitus
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits